Drug intelligence / Profile preview

BLHK03

Development stage: Preclinical
Lead developer: The University of Hong Kong
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

BLHK03 is a synbiotic formula composed of the probiotic strain *Bifidobacterium longum* HK003 and the water-soluble vitamin biotin (Vitamin B7). It is currently being investigated for its potential to alleviate chemotherapy-induced alopecia (CIA) in breast cancer patients. The probiotic component, *B. longum* HK003, was originally isolated from healthy human feces and has demonstrated protective effects against hair follicle atrophy in preclinical models of cyclophosphamide-induced hair loss. Biotin is included in the formulation to support keratin production, which is essential for hair and nail health. The therapy aims to leverage the gut-skin axis to modulate the gut microbiome and provide nutritional support to mitigate the dermatological side effects of oncological treatments.

Other names: Bifidobacterium longum HK003 + biotinsynbiotic formula BLHK03

Beyond the preview

Go deeper on BLHK03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLHK03.

Explore the full profile